Vaishali Pharma Quarterly Results
Vaishali Pharma quarterly results. In Mar 2026, Vaishali Pharma (VAISHALI) reported revenue ₹28 Cr and net profit ₹0 Cr. Check Vaishali Pharma market worth to track the company's total market size over time.
VAISHALI Quarterly Results — Revenue, Profit & EPS Highlights
Vaishali Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Vaishali Pharma share price today.
- Revenue of ₹28 Cr in Mar 2026 (+16.7% vs Jun 2026)
- EBITDA of ₹1 Cr in Mar 2026 (-50.0% vs Jun 2026)
- Operating Margin of -1.0% in Mar 2026 (-7.0pp vs Jun 2026)
- Earnings Per Share of ₹0.03 in Mar 2026 (-75.0% vs Jun 2026)
Vaishali Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VAISHALI quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 28 | 24 | 34 | 25 | 26 | 16.7% | - |
| Net Profit (₹ Cr) | 0 | 2 | 1 | 1 | 1 | - | - |
| EBITDA (₹ Cr) | 1 | 2 | 2 | 2 | 2 | - | - |
| EPS (₹) | 0.03 | 0.12 | 0.09 | 0.10 | 0.10 | - | - |
| Operating Margin (%) | -1.0% | 6.0% | 4.0% | 6.0% | 6.0% | - | - |
VAISHALI Share Price Trend — 1-Year Movement Across Quarterly Results
Vaishali Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review VAISHALI PE ratio trends to evaluate earnings-based valuation against sector peers.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VAISHALI vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vaishali Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1804.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 159.7 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9550.0 | 2,986 | 751 | -5.0% | - | 25.2% | 337.3 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1159.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 2050.0 | 1,823 | 282 | -10.5% | - | 15.5% | 396.5 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores